Eskayef Pharmaceuticals Ltd. is one of the leaders in Bangladesh’s pharmaceutical industry. With its presence across the world, it has earned coveted accreditations from the US FDA, UK MHRA, EU EMA, TGA Australia, and more. Eskayef spread its wings in 1990 when the Bangladeshi operations of SmithKline & French were acquired by Transcom Group.



Multinational SmithKline & French (SK&F) enters Bangladesh

Rectangle 2343


Transcom acquires SmithKline & French (SK&F) and becomes Eskayef Bangladesh Ltd

Rectangle 2343


Eskayef Bangladesh Ltd. emerges as Eskayef Pharmaceuticals Ltd. to go more global

Rectangle 2343


Pioneering of Pellet Technology in Bangladesh


  • Acquisition of Squibb Plant at Tongi
  • Beginning of Animal Health Business


Beginning of International Business


  • Accreditation by UK MHRA & EU GMP
  • Commissioning of Dedicated Cephalosporin Plant


Accreditation by TGA Australia


  • Accreditation by VMD UK
  • Starts manufacturing Insulin for Novo Nordisk


  • Commissioning of Sterile Unit at Tongi
  • Eskayef ventures into Eyecare segments by launching Ophthalmic Drops


  • Approval by UNICEF
  • Acquisition of Salna Plant


Commissioning of Rupgonj Plant


  • Commissioning of future-ready and state-of the art manufacturing plant, Faraaz Ayaaz Hossain Building and its accreditation by UK MHRA.
  • Launching of Carbapenem products from dedicated state-of-the-art facility


  • With the mission of fighting together and winning the battle against Cancer, Eskayef launches oncology products from its dedicated Oncology plant with 1st time in Bangladesh ISOLATOR technology
  • Eskayef establishes its state-of the art dedicated R&D Centre at Salna


  • Eskayef redefines its capability by introducing Remivir injection, the 1st generic Remdesivir brand in the world for treating hospitalized Covid-19 patients
  • Eskayef Oncology manufacturing plant receives EU GMP Approval, which is the 1st and only EU GMP certified Oncology Facility in Bangladesh


  • Eskayef introduces Monuvir brand, the 1st Generic Molnupiravir brand in the world for the treatment of COVID-19 patients
  • Eskayef introduces Paxovir brand, the 1st Generic Nirmatrelvir + Ritonavir brand in the world for the treatment of COVID-19 patients
  • Eskayef Oncology manufacturing plant receives ANVISA Brazil Approval, which is the 1st and only ANVISA certified Oncology Facility in Bangladesh


The Faraaz Ayaaz Hossain Building manufacturing facility receives the prestigious US FDA approval.

Global Quality Standards

International Accreditations

image 2 usa

YEAR: 2022

image 3 Group

YEAR: 2008, 2011, 2014, 2017

vmid Group

YEAR: 2011, 2014, 2017

image 5 Group 8620

Faraaz Ayaaz Hossain Building

Tablet, Capsule & Pellets (2017)

& Eskayef Oncology

Sterile injection & Oral Solid (2020)

image 7 Group 8619

YEAR: 2010, 2012, 2015

image 6 Group 8618

Eskayef Oncology

Sterile injection (2021)

Multinational Partners

  • Novo Nordisk

    Multinational Partners
  • Servier

    Multinational Partners

Fight Against COVID-19


Eskayef exports to 70 countries

across 6 continents in the world.

Leadership Team


Simeen Rahman

Managing Director & CEO

Rectangle 2405

Dr. Mohammad Mujahidul Islam

Executive Director - Marketing and Sales

Rectangle 2404

Mohammed Ikhtiar Hossain

Executive Director - Technical Services

Rectangle 2402

Md. Motiar Rahman

Executive Director - Quality Assurance

Rectangle 2400

Mohammad Mostafa Hassan

Executive Director - Commercial & HR

Rectangle 2401

Kazi Mahbub Masud

Executive Director - Finance

Rectangle 2403

K.M. Ariful Islam

Executive Director - Plant

Rectangle 2405 (1)

Abdullah Al Wahid

Executive Director - Plant